MYGN - Myriad Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures4

Market Cap (intraday) 1.89B
Enterprise Value 1.97B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) 1.40
Price/Sales (ttm)2.70
Price/Book (mrq)2.26
Enterprise Value/Revenue 2.84
Enterprise Value/EBITDA -18.82

Trading Information

Stock Price History

Beta (5Y Monthly) 1.84
52-Week Change 332.88%
S&P500 52-Week Change 36.21%
52 Week High 328.18
52 Week Low 313.92
50-Day Moving Average 321.51
200-Day Moving Average 320.21

Share Statistics

Avg Vol (3 month) 3589.81k
Avg Vol (10 day) 3633.99k
Shares Outstanding 581.56M
Implied Shares Outstanding 6N/A
Float 868.71M
% Held by Insiders 12.10%
% Held by Institutions 1102.49%
Shares Short (May 14, 2023) 43.77M
Short Ratio (May 14, 2023) 47.22
Short % of Float (May 14, 2023) 46.65%
Short % of Shares Outstanding (May 14, 2023) 44.63%
Shares Short (prior month Apr 13, 2023) 43.74M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 22:1
Last Split Date 3Mar 25, 2009

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2022
Most Recent Quarter (mrq)Mar 30, 2023


Profit Margin -21.04%
Operating Margin (ttm)-20.71%

Management Effectiveness

Return on Assets (ttm)-7.42%
Return on Equity (ttm)-16.38%

Income Statement

Revenue (ttm)694.7M
Revenue Per Share (ttm)8.59
Quarterly Revenue Growth (yoy)9.90%
Gross Profit (ttm)476.4M
Net Income Avi to Common (ttm)-146.2M
Diluted EPS (ttm)-1.85
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)78.7M
Total Cash Per Share (mrq)0.96
Total Debt (mrq)161.6M
Total Debt/Equity (mrq)19.35
Current Ratio (mrq)1.83
Book Value Per Share (mrq)10.25

Cash Flow Statement

Operating Cash Flow (ttm)-93M
Levered Free Cash Flow (ttm)-107.89M